| Jun 26 |
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
|
| Jun 24 |
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
|
| Jun 24 |
Valneva’s chikungunya vaccine wins Canada approval
|
| Jun 24 |
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
|
| Jun 5 |
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
|
| Jun 4 |
VALNEVA - Declaration of shares and voting rights: May 31, 2024
|
| Jun 4 |
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
|
| Jun 3 |
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
|
| May 31 |
Valneva nabs EU backing for Chikungunya vaccine
|
| May 31 |
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
|
